Acura Pharmaceuticals Inc. (ACUR) PT Set at $6.00 by Roth Capital
Acura Pharmaceuticals Inc. (NASDAQ:ACUR) received a $6.00 price objective from investment analysts at Roth Capital in a note issued to investors on Tuesday. The brokerage currently has a a “buy” rating on the specialty pharmaceutical company’s stock. Roth Capital’s price objective points to a potential upside of 405.73% from the company’s current price.
Separately, FBR & Co reissued a “buy” rating and set a $10.00 target price on shares of Acura Pharmaceuticals in a research report on Thursday, August 11th.
Shares of Acura Pharmaceuticals (NASDAQ:ACUR) traded down 3.07% on Tuesday, reaching $1.15. 35,423 shares of the company’s stock were exchanged. Acura Pharmaceuticals has a 52-week low of $1.04 and a 52-week high of $3.52. The stock’s market cap is $13.61 million. The company’s 50 day moving average price is $1.55 and its 200-day moving average price is $2.11.
Acura Pharmaceuticals (NASDAQ:ACUR) last released its earnings results on Monday, August 8th. The specialty pharmaceutical company reported ($0.28) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.28). Acura Pharmaceuticals had a negative net margin of 303.77% and a negative return on equity of 178.04%. Equities analysts forecast that Acura Pharmaceuticals will post ($1.05) EPS for the current fiscal year.
A hedge fund recently raised its stake in Acura Pharmaceuticals stock. Renaissance Technologies LLC increased its stake in Acura Pharmaceuticals Inc. (NASDAQ:ACUR) by 10.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 58,120 shares of the specialty pharmaceutical company’s stock after buying an additional 5,300 shares during the period. Renaissance Technologies LLC owned 0.49% of Acura Pharmaceuticals worth $164,000 at the end of the most recent quarter. Institutional investors and hedge funds own 32.63% of the company’s stock.
About Acura Pharmaceuticals
Acura Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products.
Receive News & Stock Ratings for Acura Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.